Oryzon Genomics S.A.
ORYZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -10.15 | 1.08 | 2.02 | -0.85 |
| FCF Yield | -13.23% | -15.47% | -12.57% | -10.20% |
| EV / EBITDA | -24.42 | -22.31 | -23.24 | -19.74 |
| Quality | ||||
| ROIC | -2.77% | -2.48% | -3.72% | -5.08% |
| Gross Margin | 95.89% | 98.28% | 97.04% | 92.97% |
| Cash Conversion Ratio | 1.02 | 0.17 | 0.44 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.32% | 10.16% | 18.14% | 1.08% |
| Free Cash Flow Growth | 11.13% | 6.46% | -4.75% | -9.60% |
| Safety | ||||
| Net Debt / EBITDA | -1.28 | -0.32 | 0.72 | 2.17 |
| Interest Coverage | -3.98 | -2.40 | -4.91 | -15.39 |
| Efficiency | ||||
| Inventory Turnover | 101.47 | 40.42 | 47.37 | 7.19 |
| Cash Conversion Cycle | -2,495.98 | -5,053.36 | -3,952.03 | -1,328.45 |